Login / Signup

Enabling robust assessment of QTc prolongation in early phase clinical trials.

Devan V MehrotraLi FanFang LiuKuenhi Tsai
Published in: Pharmaceutical statistics (2017)
Since the implementation of the International Conference on Harmonization (ICH) E14 guideline in 2005, regulators have required a "thorough QTc" (TQT) study for evaluating the effects of investigational drugs on delayed cardiac repolarization as manifested by a prolonged QTc interval. However, TQT studies have increasingly been viewed unfavorably because of their low cost effectiveness. Several researchers have noted that a robust drug concentration-QTc (conc-QTc) modeling assessment in early phase development should, in most cases, obviate the need for a subsequent TQT study. In December 2015, ICH released an "E14 Q&As (R3)" document supporting the use of conc-QTc modeling for regulatory decisions. In this article, we propose a simple improvement of two popular conc-QTc assessment methods for typical first-in-human crossover-like single ascending dose clinical pharmacology trials. The improvement is achieved, in part, by leveraging routinely encountered (and expected) intrasubject correlation patterns encountered in such trials. A real example involving a single ascending dose and corresponding TQT trial, along with results from a simulation study, illustrate the strong performance of the proposed method. The improved conc-QTc assessment will further enable highly reliable go/no-go decisions in early phase clinical development and deliver results that support subsequent TQT study waivers by regulators.
Keyphrases
  • clinical trial
  • healthcare
  • transcription factor
  • randomized controlled trial
  • primary care
  • heart failure
  • endothelial cells
  • emergency department
  • pulmonary hypertension
  • pulmonary artery
  • aortic dissection